Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Corson

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesotheliomaD J Sugarbaker, G M Strauss, T J Lynch, et al.
Oncogene|December 7, 2010
AXL regulates mesothelioma proliferation and invasivenessW-B Ou, J M Corson, D L Flynn, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group BN J Vogelzang, M Goutsou, J M Corson, et al.
Cancer|February 1, 1983
Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control studyK H Antman, R H Blum, R E Wilson, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 1, 1986
Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trialsR E Wilson, W C Wood, H L Lerner, et al.
Cancer|April 29, 1998
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group BB L Samuels, J E Herndon, D C Harmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group BA P Chahinian, K Antman, M Goutsou, et al.
The New England Journal of Medicine|February 14, 1991
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumorsJ A Fletcher, H P Kozakewich, F A Hoffer, et al.
Cancer|June 1, 1997
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group BN J Yogelzang, J E Herndon, C Cirrincione, et al.
Neonatology|August 9, 2007
Effects of lipid-supplemented total parenteral nutrition on fatty liver disease in a premature neonatal piglet modelMatthew J Hyde, Encarnación Amusquivar, John Laws, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesotheliomaD J Sugarbaker, G M Strauss, T J Lynch, et al.
Oncogene|December 7, 2010
AXL regulates mesothelioma proliferation and invasivenessW-B Ou, J M Corson, D L Flynn, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group BN J Vogelzang, M Goutsou, J M Corson, et al.
Cancer|February 1, 1983
Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control studyK H Antman, R H Blum, R E Wilson, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 1, 1986
Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trialsR E Wilson, W C Wood, H L Lerner, et al.
Cancer|April 29, 1998
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group BB L Samuels, J E Herndon, D C Harmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group BA P Chahinian, K Antman, M Goutsou, et al.
The New England Journal of Medicine|February 14, 1991
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumorsJ A Fletcher, H P Kozakewich, F A Hoffer, et al.
Cancer|June 1, 1997
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group BN J Yogelzang, J E Herndon, C Cirrincione, et al.
Neonatology|August 9, 2007
Effects of lipid-supplemented total parenteral nutrition on fatty liver disease in a premature neonatal piglet modelMatthew J Hyde, Encarnación Amusquivar, John Laws, et al.
Pageof 13